An inconclusive biopsy means the pathologist who examined your tissue sample couldn’t make a definitive diagnosis from what they saw. It doesn’t mean you have cancer, and it doesn’t mean you’re in the clear. It means the sample didn’t provide enough information to say one way or the other, and more testing is typically needed.
Why a Biopsy Comes Back Inconclusive
There are two broad categories of reasons: technical problems with the sample itself, and biological ambiguity in the tissue.
On the technical side, the needle may not have captured enough tissue to analyze properly. The sample might have been crushed during collection, poorly preserved, or too small for the pathologist to work with. The experience of the person performing the biopsy matters here. Even when imaging guidance is used to direct the needle, the specimen can still come back inadequate. For breast biopsies using fine needle aspiration, roughly 18% of samples are inadequate. Switching to a core needle biopsy, which collects a larger cylinder of tissue, drops that rate to about 7%.
Biological ambiguity is the other major factor. Sometimes the tissue looks unusual under the microscope but doesn’t clearly fit into a “benign” or “malignant” category. Cells can show features that overlap between normal, inflamed, precancerous, and cancerous tissue. A pathologist seeing a small cluster of slightly abnormal cells may not have enough evidence to call it cancer, but can’t confidently rule it out either. One study of imaging-guided biopsies found that about 21% came back indeterminate, with findings like inflammation, structural tissue, or atypical cells that didn’t point clearly in either direction.
Common Terms You Might See on Your Report
Your pathology report might not use the word “inconclusive.” Instead, you may see terms like “non-diagnostic,” “indeterminate,” “atypical cells of undetermined significance,” or “suspicious but not diagnostic.” These all fall under the same umbrella: the pathologist sees something that needs further investigation but can’t make a firm call.
In prostate biopsies, one specific term is “atypical small acinar proliferation,” or ASAP. This means the pathologist found small clusters of glands that look somewhat abnormal but aren’t numerous or distinctive enough to diagnose as cancer. ASAP is not a precancerous condition. It could represent a benign process that mimics cancer under the microscope, or it could mean the needle just barely clipped the edge of something that a larger sample would clarify.
For thyroid biopsies, doctors use a six-tier system called the Bethesda classification. Categories III and IV are the inconclusive zones. Category III, labeled “atypia of undetermined significance,” carries a malignancy risk of roughly 10 to 30%. Category IV, “suspicious for follicular neoplasm,” has a somewhat higher risk of 25 to 40%. These ranges are wide because the findings genuinely sit in a gray area, and the actual cancer rate depends heavily on the individual case.
How Common Are Inconclusive Results?
Inconclusive findings are not rare, and they’re not a sign that something went wrong. In thyroid fine needle aspirations, about 7% come back formally indeterminate, with an additional 6 to 7% classified as non-diagnostic (meaning the sample wasn’t usable at all). Roughly 60 to 70% of thyroid biopsies are benign, 5 to 10% are malignant, and the remainder fall into the inconclusive or suspicious categories.
Rates vary by the type of biopsy and the organ involved. Fine needle aspirations, which use a thin needle to extract individual cells, tend to have higher inconclusive rates than core needle biopsies, which remove a small cylinder of intact tissue that preserves the architecture pathologists need to see.
What Happens Next
Your doctor will recommend one of several paths depending on why the result was inconclusive and what organ was biopsied.
- Repeat biopsy: The most common next step. A second attempt often succeeds where the first didn’t, especially if the initial sample was simply too small. In one study of inconclusive pancreatic biopsies, a repeated needle biopsy was sufficient to establish a diagnosis in 36 out of 46 cases.
- Different biopsy technique: If a fine needle aspiration was inconclusive, your doctor may recommend a core needle biopsy or a surgical biopsy, which removes a larger piece of tissue. Larger samples give the pathologist more to work with and reduce ambiguity.
- Molecular testing: For indeterminate thyroid nodules especially, genetic tests can analyze the biopsy sample for mutations associated with cancer. These tests examine dozens to over a hundred genes linked to thyroid cancer. Some are designed to “rule out” cancer, with a negative result giving roughly 95 to 97% confidence that the nodule is benign. Others are designed to “rule in” cancer, with a positive result giving high confidence that it is malignant. These tests can help you and your doctor decide whether surgery is necessary or whether monitoring is a safe option.
- Pathology second opinion: Another pathologist may review the same slides with fresh eyes. This is common at academic medical centers, where subspecialists focus on specific tissue types.
- Active surveillance: In some cases, particularly when the suspicion for cancer is low, your doctor may recommend monitoring with repeat imaging over months rather than immediately repeating the biopsy.
How Long Results Take
Standard biopsy results are supposed to be reported within two working days for routine cases, according to pathology accreditation standards. In practice, about a quarter of routine cases take longer than that. If your biopsy requires additional staining, immunohistochemistry, or a specialist review, the timeline extends further. Molecular testing on an inconclusive thyroid biopsy can add one to three weeks on top of the initial report.
If your result comes back inconclusive and a repeat biopsy is recommended, the wait for the second procedure and its results can stretch the overall timeline to several weeks or longer. This waiting period is genuinely stressful, but it reflects the complexity of making an accurate diagnosis rather than a problem with your care.
What Inconclusive Does Not Mean
An inconclusive result is not a soft way of delivering bad news. It is a literal statement that the evidence is insufficient. Many inconclusive biopsies turn out to be benign on follow-up. In the thyroid, where inconclusive results are well studied, roughly 75% of Category III nodules and 72% of Category IV nodules are ultimately not cancerous when surgically removed and fully examined.
It also doesn’t mean your doctor made a mistake. Some tissue simply doesn’t cooperate. Small nodules are harder to target. Deep organs are harder to reach. And some conditions produce cells that genuinely look ambiguous, even to experienced pathologists. The important thing is that a clear follow-up plan exists, and that you understand what your specific next step is.